

LIST OF TABLES

- Table 2.1 Small molecules Kinase inhibitors in clinical development
- Table 3.1 Statistical parameters from the validation of the pharmacophore model by mean of decoy set
- Table 3.2 Information of statistical significance and predictive power presented in cost values measured in bits for top 10 hypotheses as a result of automated HypoGen pharmacophore generation process
- Table 3.3 Experimental biological data and estimated IC₅₀ of training set molecules based on pharmacophore model Hypo1
- Table 3.4 Experimental biological data and estimated IC₅₀ of test set molecules based on pharmacophore model Hypo 1.
- Table 3.5 The estimated activity, interaction energy and LigandFit scoring results of top ranked four compounds obtained from the combination of Hypo1 based virtual screening and molecular docking studies
- Table 4.1 Detailed structures of natural compounds used for study
- Table 4.2 Top Docking scores of natural compounds with receptor protein
- Table 5.2 ADMET results of Myricetin and their Analogues
- Table 5.2 ADMET results of Myricetin and their Analogues
- Table 5.3 Toxicity profile of all screened ligands using Toxicity Prediction – Extensible protocol of Accelrys Discovery Studio 2.5

